文献速递慢性肾脏病肾血管病与高血压

血清尿调节素与老年人心血管疾病及死亡风险的关联:心血管健康研究

Association of serum uromodulin with mortality and cardiovascular disease in the elderly-the Cardiovascular Health Study.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

BACKGROUND: Uromodulin (UMOD) is released by renal tubular cells into the serum (sUMOD) and urine. Lower urine UMOD has been linked to mortality and cardiovascular disease but much less is known about sUMOD.…

要点

  • sUMOD与心衰风险的关联未达统计学显著性。

核心结论

  • 在社区老年人中,较高的sUMOD水平与较低的全因死亡和心血管疾病风险独立相关。

研究设计与样本

  • 研究为前瞻性队列研究,纳入心血管健康研究中随机抽取的933名社区老年人,测量基线sUMOD并随访中位9.9年。

主要发现

  • sUMOD处于较低四分位数的参与者eGFR较低且白蛋白尿较高(P < 0.01)。
  • 多变量分析中,sUMOD每升高1个标准差,全因死亡风险比为0.89(95%CI 0.80-0.99),心血管疾病风险比为0.80(95%CI 0.67-0.96),复合终点风险比为0.88(95%CI 0.78-0.99)。
  • sUMOD与心衰风险的关联无统计学意义(HR 0.84,95%CI 0.70-1.01)。

关键数值与推荐

  • 分析时排除了sUMOD分布两端各2.5%的数值,sUMOD范围限定为34.3-267.1 ng/mL。
  • 基线平均年龄78 ± 5岁,男性占40%,sUMOD平均水平127 ± 64 ng/mL,eGFR为63 mL/min/1.73 m2,42%的参与者eGFR <60 mL/min/1.73 m2。
  • 随访期间共805例死亡,283例发生心衰,274例发生心血管疾病。

临床怎么用

  • sUMOD可作为老年人群死亡和心血管疾病风险的潜在生物标志物,但尚需进一步研究验证其临床效用。

局限性

  • 研究排除了sUMOD分布两端各2.5%的数值,可能限制对极端值关联的解读。
  • 研究为观察性设计,无法确定因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uromodulin (UMOD) is released by renal tubular cells into the serum (sUMOD) and urine. Lower urine UMOD has been linked to mortality and cardiovascular disease but much less is known about sUMOD. We evaluated the association of sUMOD with these outcomes in community-dwelling older adults. METHODS: We measured sUMOD in a random subcohort of 933 participants enrolled in the Cardiovascular Health Study. The associations of sUMOD with all-cause mortality, incident heart failure (HF) and incident cardiovascular disease (CVD; myocardial infarction, stroke and mortality due to coronary disease or stroke) were evaluated using multivariable Cox regression, adjusting for study participants' demographics, estimated glomerular filtration rate (eGFR), albuminuria and CVD risk factors. Generalized additive models with splines were used to address the functional form of sUMOD with outcomes. Due to nonlinear associations of sUMOD with all outcomes, 2.5% of the values on either end of the sUMOD distribution were excluded from the analyses, limiting the range of sUMOD to 34.3-267.1 ng/mL. RESULTS: The mean age was 78 ± 5 years, 40% were male, sUMOD level was 127 ± 64 ng/mL, eGFR was 63 mL/min/1.73 m2 and 42% had CKD defined as eGFR <60 mL/min/1.73 m2. Patients in the lower sUMOD quartiles had lower eGFR and higher albuminuria (P < 0.01, respectively). During a median follow-up of 9.9 years, 805 patients died, 283 developed HF and 274 developed CVD. In multivariable analysis, higher sUMOD was significantly associated with a lower hazard for mortality {hazard ratio [HR] 0.89 [95% confidence interval (CI) 0.80-0.99] per 1 standard deviation (SD) higher sUMOD}, CVD [HR 0.80 (95% CI 0.67-0.96)] and the composite endpoint [HR 0.88 (95% CI 0.78-0.99)]; the association with HF was not statistically significant [HR 0.84 (95% CI 0.70-1.01)]. CONCLUSION: Higher sUMOD is independently associated with a lower risk for mortality and CVD in older adults.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Steubl D, Buzkova P, Garimella PS, et al. Association of serum uromodulin with mortality and cardiovascular disease in the elderly-the Cardiovascular Health Study. Nephrol Dial Transplant. 2020. PMID: 30903163. doi:10.1093/ndt/gfz008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。